Journal Mobile Options
Table of Contents
Vol. 11, No. 1, 2005
Issue release date: 2005
Eur Addict Res 2005;11:44–49

QTc Interval Prolongation in Patients on Long-Term Methadone Maintenance Therapy

Maremmani I. · Pacini M. · Cesaroni C. · Lovrecic M. · Perugi G. · Tagliamonte A.
aPISA-SIA (Study and Intervention on Addictions) Group ‘Santa Chiara’, University Hospital, Department of Psychiatry, NFB, University of Pisa, bInstitute of Behavioral Sciences ‘G. De Lisio’, Carrara, cAssociation for the Application of Neuroscientific Knowledge to Social Aims (AU-CNS onlus), Pietrasanta, LU, dSerT ASL 22 Novi Ligure-Ovada-Aqui Terme, and eDepartment of Neurosciences, Pharmacology Section, University of Siena, Italy; fInstitute of Health of the Republic of Slovenia, Ljubljana, Slovenia

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Objective: The aim of the present study was to assess the incidence of abnormal QTc interval values in a population of subjects on a long-term methadone maintenance treatment, as a single therapy, and with methadone dosages ranging between 10 and 600 mg/daily (mean ± SD = 87 ± 76). Method: Basal ECG recordings were carried out in 83 former heroin addicts on long-term successful methadone maintenance therapy for at least 6 months, while no other known QT-prolonging agent was being administered. Results: Eighty-three percent of the subjects had a more prolonged QT interval than the reference values for persons of the same sex and age. Only 2 patients displayed a QTc interval of >500 ms. No correlation emerged between QTc values and methadone dosages. Conclusion: Patients on long-term methadone maintenance treatment show longer than expected QTc interval values. This data, associated with the finding that methadone is a rather potent inhibitor of HERG potassium channels and that it may induce torsade de pointes in predisposed subjects, supports the recommendation that patients entering methadone treatment (MT) are screened for cardiac risk factors. ECG might be considered in ongoing MT patients especially before starting QT-prolonging medications.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Al-Khatib SM, LaPointe NMA, Kramer JM, Califf RM: What clinicians should know about the QT interval. JAMA 3003;289:2120–2127.
  2. Backmund M, Meyer K, Zwehl W, Nagengast O, Eichenlaub D: Myocardial infarction associated with methadone and/or dihydrocodeine. Eur Add Res 2001;7:37–39.
  3. Barhanin J, Lesage F, Guillemare E, Fink M, Lazdunski M, Romey G: KvLQT1 and IsK (minK) proteins associate to form the Iks cardiac potassium current. Nature 1996;384:78–80.
  4. Bazett HC: An analysis of time relations of electrocardiograms. Heart 1920;7:353–367.
  5. Clancy CE, Kurokawa J, Tateyama M, Wehrens XHT, Kass RS: K+ channel structure-activity relationships and mechanisms of drug-induced QT prolongation. Annu Rev Pharmacol Toxicol 2003;43:441–461.
  6. Clancy CE, Rudy Y: Cellular consequences of HERG mutations in the long QT syndrome: Precursors to sudden cardiac death. Cardiovasc Res 2001;50:301–313.
  7. Cubeddu LX: QT prolongation and fatal arrhythmias: A review of clinical implications and effects of drugs. Am J Ther 2003;10:452–457.
  8. De Ponti F, Poluzzi E, Montanaro N: QT interval prolongation by non-cardiac drugs: Lessons to be learned from recent experience. Eur J Clin Pharmacol 2000;56:1–18.
  9. Eap CB, Deglon JJ, Baumann P: Pharmacokinetics and pharmacogenetics of methadone: Clinical relevance (Notes: Review Article). Heroin Add Rel Clin Probl 1999;1:19–34.
  10. El Sherif N, Chinushi M, Caref EB, Restivo M: Electrophysiological mechanism of the characteristic electrocardiographic morphology of torsade de pointes tachyarrhythmias in the long-QT syndrome: Detailed analysis of ventricular tridimensional activation patterns. Circulation 1997;96:4392–4399.
  11. EMEA: EMEA Public Statement on Levacetylmethadol (ORLAAM) Life-Threatening Cardiac Rhythm Disorders. No. 38436/99. London, EMEA, 1999.
  12. EMEA: EMEA Public Statement on the recommendation to suspend the marketing authorization for Orlaam (levoacetylmethadol) in the European Union. No. 8776/01. London, EMEA, 2001.
  13. Gil M, Sala M, Anguera I, Chapinal O, Cervantes M, Guma JR, Segura F: QT prolongation and torsades de pointes in patients infected with human immunodeficiency virus and treated with methadone. Am J Cardiol 2003;92 8:995–997.
  14. Hancox JC, Witchel HJ: Psychotropic drugs, HERG, and the heart. Lancet 2000;356:428.
  15. Katchman AN, McGroary KA, Kilborn MJ, Kornick CA, Manfredi PL, Woosley RL, Ebert SN: Influence of opioid agonists on cardiac human ether-a-go-go related gene K+ current. J Pharmacol Exp Ther 2002;303:688–694.
  16. Kirchhof P, Eckardt L, Franz MR, Monnig G, Loh P, Wedekind H, Schulze-Bahr E, Breithardt G, Haverkamp W: Prolonged atrial action potential durations and polymorphic atrial tachyarrhythmias in patients with long QT syndrome. J Cardiovasc Electrophysiol 2003;14:1027–1033.
  17. Kornick CA, Kilborn MJ, Santiago-Palma J, Schulman G, Thaler HT, Keefe DL, Katchman AN, Pezzullo JC, Ebert SN, Woosley RL, Payne R, Manfredi PL: QTc interval prolongation associated with intravenous methadone. Pain 2003;105:499–506.
  18. Krantz MJ, Kutinsky IB, Robertson AD, Mehler PS: Dose-related effects of methadone on QT prolongation in a series of patients with torsade de pointes. Pharmacotherapy 2003;23:802–805.
  19. Krantz MJ, Lewkowicz L, Hays H, Woodroffe MA, Robertson AD, Mehler PS: Torsade de pointes associated with very-high-dose methadone. Ann Intern Med 2002;137:501–504.
  20. Krantz MJ, Mehler PS: Synthetic opioids and QT prolongation. Arch Intern Med 2003;163:1615.
  21. Leavitt SB: The safety of methadone, LAAM, buprenorphine in the treatment of opioid dependency. Addict Treatm Forum 2001;10:1–10.
  22. Mathot F, Kurz X, Noel CH, Firket P: Long QTc and psychotropic drug use. Int J Neuropsychopharmacol 2000;3(suppl 1):173.
  23. McCormack KJ, Chapleo CB: Opioid receptors and myocardial protection: Do opioid agonists possess cardioprotective effects? Clin Drug Invest 1998;15:445–454.
  24. Meyer JS, Mehdirad A, Salem BI, Kulikowska A, Kulikowski P: Sudden arrhythmia death syndrome: Importance of the long QT syndrome. Am Fam Physician 2003;68:483–488.
  25. Mohammed S, Zhou Z, Gong Q, January CT: Blockade of the HERG human cardiac K+ channel by the gastrointestinal prokinetic agent cisapride. Am J Physiol 1997;273:H2534–H2538.
  26. Moss AJ: Drugs that prolong the QT interval: Regulatory and QT measurement issues from the United States and European perspectives. Ann Noninvas Electrocardiol 1999;4:255–256.

    External Resources

  27. Reilly JG, Ayis SA, Ferrier IN, Jones SJ, Thomas SHL: QT interval abnormalities and psychotic drug therapy in psychiatric patients. Lancet 2000;355:1048–1052.
  28. Robbins J, Nelson JC, Rautaharju PM, Gottdiener JS: The association between the length of the QT interval and mortality in the cardiovascular health study. Am J Med 2003;115:689–694.
  29. Roden DM: Acquired long QT syndromes and the risk of proarrhythmia. J Cardiovasc Electrophysiol 2000;11:938–940.
  30. Sanguinetti MC, Curran ME, Zou A, Shen J, Spector PS, Atkinson DL, Keating MT: Coassembly of K(V)LQT1 and minK (IsK) proteins to form cardiac I(Ks) potassium channel. Nature 1996;384:80–83.
  31. Sanguinetti MC, Jiang C, Curran ME, Keating MT: A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the Ikr potassium channel. Cell 1995;81:299–307.
  32. Stimmel B, Lipski J, Swartz M, Donoso E: Electrocardiographic changes in heroin, methadone and multiple drug abuse: A postulated mechanism of sudden death in narcotic addicts. Proc Natn Conf Methadone Treatm 1973;1:706–710.
  33. Towbin JA, Vatta M: Molecular biology and the prolonged QT syndromes. Am J Med 2001;110:385–398.
  34. Vincent GM: The molecular genetics of the long QT syndrome: Genes causing fainting and sudden death. Annu Rev Med 1998;49:263–274.
  35. Vincent GM, Timothy K, Leppert M, Keating M: The spectrum of symptoms and QT interval in carriers of the gene for the long-QT syndrome. N Engl J Med 1992;327:846–852.
  36. Viswanathan PC, Rudy Y: Cellular arrhythmogenic effects of congenital and acquired long-QT syndrome in the heterogeneous myocardium. Circulation 2000;101:1192–1198.
  37. Wang Q, Curram ME: Positional cloning of a novel potassium channel gene: QVLQT1 mutations cause cardiac arrhythmias. Nat Genet 1996;12:17–23.
  38. Warmke JW, Ganetzsky B: A family of potassium channel genes related to eag in drosophila and mammals. Proc Natl Acad Sci USA 1994;91:3438–3442.
  39. Welch R, Chue P: Antipsychotic agents and QT changes. J Psychiatry Neurosci 2000;25:154–160.
  40. Woosley RL: International Registry of Drug-Induced Arrhythmias. Georgetown University Center for Education and Research on Therapeutics. Available Online at: http://QTdrugs.Org. 2001.
  41. Zhou Z, Gong Q, Ye B, Fan Z, Makielski JC, Robertson GA, January CT: Properties of HERG channels stably expressed in HEK 293 cells studied at physiological temperature. Biophys J 1998;74:230–241.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50